Markets:

Overview

News

Currencies

International

Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

22.14 +0.42 (+1.93%)

Streaming Delayed Price Updated: 10:56 AM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 13, 2022

Gainers

Via Benzinga

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests ↗

July 13, 2022

Via Benzinga

Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment

July 13, 2022

From Innoviva, Inc.

Via Business Wire

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share ↗

May 23, 2022

Via Benzinga

La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News ↗

July 11, 2022

A headline-grabbing takeover deal could be impactful for the medical community - and today, it's definitely huge news for LJPC stock holders.

Via InvestorPlace

Innoviva Completes Acquisition of Entasis Therapeutics

July 11, 2022

From Innoviva, Inc.

Via Business Wire

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗

July 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal ↗

July 11, 2022

Via Benzinga

Innoviva to Acquire La Jolla Pharmaceutical Company

July 11, 2022

From La Jolla Pharmaceutical Company

Via Business Wire

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

July 08, 2022

From Innoviva, Inc.

Via Business Wire

5 Value Stocks To Watch In The Healthcare Sector ↗

June 27, 2022

What Defines a Value Stock?

Via Benzinga

Innoviva to Acquire Entasis Therapeutics

May 23, 2022

From Innoviva, Inc.

Via Business Wire

Innoviva Reports First Quarter 2022 Financial Results

April 27, 2022

From Innoviva, Inc.

Via Business Wire

Overview Of Value Stocks In The Healthcare Sector ↗

March 28, 2022

What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

Sail Through the Choppy Market With These 4 Low-Beta Stocks ↗

March 05, 2022

Creating a portfolio of low-beta stocks is important since the securities can deliver healthy returns and provide a shield against volatile market conditions.

Via Talk Markets

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 11, 2022

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock rose 29.0% to $1.38 during Friday's pre-market session. The company's market cap stands at $11.4 million. Innoviva...

Via Benzinga

62 Biggest Movers From Yesterday ↗

February 11, 2022

Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 42.8% to close at $3.07 on Thursday following the company's recent uplisting to the Nasdaq....

Via Benzinga

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗

February 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Armata Pharma's Largest Shareholder Injects $45M For Its Bacteriophage Development ↗

February 10, 2022

Armata Pharmaceuticals Inc (NYSE: ARMP) has

Via Benzinga

Innoviva Reports Fourth Quarter 2021 Financial Results

February 09, 2022

From Innoviva, Inc.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

February 02, 2022

Good morning, investor! We're beginning another busy day of trading with a look at the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

10 Stocks to Buy That Could Make You a Millionaire in 2022 ↗

January 26, 2022

After this past year, it's going to be hard to find stocks to buy to make you a millionaire in 2022. Here are 10 that might do the trick.

Via InvestorPlace

7 of the Top-Rated Pharmaceutical Stocks for Q1 ↗

January 18, 2022

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks.

Via InvestorPlace

5 Value Stocks In The Healthcare Sector ↗

December 20, 2021

What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

December 06, 2021

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples...

Via Benzinga

Innoviva Reports Third Quarter 2021 Financial Results

October 27, 2021

From Innoviva, Inc.

Via Business Wire

Beam Therapeutics Stock Flashes Renewed Technical Strength ↗

October 12, 2021

On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before.

Via Investor's Business Daily

Innoviva Stock In Buy Range; Joins Ranks Of Top-Performing Stocks With Strength Ratings Over 90 ↗

October 08, 2021

Innoviva stock is within a buy range after climbing above a 16.82 entry in a flat base. The proper buying range is up to 5% above the entry.

Via Investor's Business Daily

Alkermes Stock Composite Rating Rises To Near-Perfect 96 As It Posts Erratic But Huge Sales Gains ↗

October 05, 2021

The IBD SmartSelect Composite Rating for Alkermes rose from 94 to 96 Tuesday.

Via Investor's Business Daily

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.